Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Solid Tumors Refractory to Standard Therapy”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT00339144
What this trial is testing

Study of Dasatinib (BMS-354825) in Patients With Solid Tumors

Who this might be right for
Tumors
Bristol-Myers Squibb 16
Not applicableUnknownNCT06009835
What this trial is testing

DOTr/DOTa Algorithm Guidance for Refractory Solid Tumors

Who this might be right for
Solid TumorIndividuation
Tianjin Medical University Second Hospital 15
Early research (Phase 1)Ended earlyNCT00358397
What this trial is testing

One Time Injection of Bacteria to Treat Solid Tumors That Have Not Responded to Standard Therapy

Who this might be right for
Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2
Testing effectiveness (Phase 2)Active Not RecruitingNCT05605496
What this trial is testing

NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies

Who this might be right for
Advanced Solid TumorsMetastatic Solid Tumors
Centre Leon Berard 57
Early research (Phase 1)Study completedNCT02499224
What this trial is testing

Safety and Pharmacokinetics Study of YYB101 in Advanced Solid Tumors Patients Who Are Refractory to Standard Therapy

Who this might be right for
Solid Tumors
CellabMED 39
Early research (Phase 1)Study completedNCT00509613
What this trial is testing

Phase 1 Study With Sorafenib and Sirolimus

Who this might be right for
Advanced Solid TumorRefractory to Standard Therapies
Radboud University Medical Center
Testing effectiveness (Phase 2)Study completedNCT00598975
What this trial is testing

NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b)

Who this might be right for
TumorColorectal Cancer
Nektar Therapeutics 18
Testing effectiveness (Phase 2)Looking for participantsNCT06911333
What this trial is testing

AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Solid Tumor, AdultTumor, SolidSolid Tumor+4 more
Avelos Therapeutics Inc. 36
Early research (Phase 1)Study completedNCT00816400
What this trial is testing

A Dose Escalation, Dose Expansion Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-575, in Subjects With Advanced Tumors.

Who this might be right for
Cancer
MedImmune LLC 49
Early research (Phase 1)Study completedNCT00949949
What this trial is testing

Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy

Who this might be right for
Cholangiocarcinoma of the GallbladderLocalized Gallbladder CancerUnresectable Gallbladder Cancer+1 more
Mayo Clinic 38
Early research (Phase 1)Study completedNCT04676633
What this trial is testing

Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy

Who this might be right for
Hepatocellular CarcinomaLiver MetastasesCholangiocarcinoma
Sirnaomics 5
Early research (Phase 1)Ended earlyNCT01118819
What this trial is testing

Safety Study of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies

Who this might be right for
Solid Tumor Malignancies
BioMed Valley Discoveries, Inc 5
Early research (Phase 1)Study completedNCT00633269
What this trial is testing

Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic Tumours

Who this might be right for
Neoplasm Metastasis
AstraZeneca 6
Testing effectiveness (Phase 2)Study completedNCT00284817
What this trial is testing

Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer

Who this might be right for
Cancer
MedImmune LLC 17
Early research (Phase 1)Study completedNCT00839631
What this trial is testing

Dose Escalation Study of EC D-3263 HCl in Advanced Solid Tumors

Who this might be right for
Solid Tumors
Dendreon 23
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06400160
What this trial is testing

Clinical Trial of TB511 in Advanced Solid Tumors

Who this might be right for
NSCLCProstate CancerColorectal Cancer+1 more
Twinpig Biolab, Inc. 12
Early research (Phase 1)Study completedNCT01346358
What this trial is testing

IMC-CS4 in Subjects With Advanced Solid Tumors

Who this might be right for
Neoplasms
Eli Lilly and Company 52
Early research (Phase 1)Study completedNCT01014936
What this trial is testing

First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors

Who this might be right for
Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available
EMD Serono 149
Early research (Phase 1)Study completedNCT01209143
What this trial is testing

Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

Who this might be right for
Solid Cancers
Genentech, Inc. 52
Early research (Phase 1)Study completedNCT00027898
What this trial is testing

Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Who this might be right for
Unspecified Adult Solid Tumor, Protocol Specific
National Cancer Institute (NCI) 27
Next Page